- All News
- In the News
- Press Releases
- Noteworthy Articles
The effect of uncertainty in patient classification on diagnostic performance estimations
Background The performance of a new diagnostic test is typically evaluated against a comparator which is assumed to correspond closely to some true state of interest. Judgments about the new test’s performance are based on the differences between the outputs of the test and comparator. It is commonly assumed that...
Novacyt, Immunexpress Extend Sepsis Assay Development Partnership
French diagnostics firm Novacyt said today that its molecular testing division Primerdesign has extended its sepsis assay development contract with Immunexpress. Specific terms of the deal were not disclosed. Novacyt said the companies have been working together for three years, with Primerdesign providing Immunexpress with assay development services....
Disagreement in Sepsis Diagnosis is Associated with Significant Antibiotic Overprescription
Immunexpress, Inc., a molecular diagnostics company based in Seattle, announced the publication of a study, in the Journal of Intensive Care, demonstrating the challenge physicians face in making accurate and consistent clinical diagnoses of sepsis in intensive care patients. Sepsis is an illness caused by the body's overwhelming immune response to an infection,...
Medical Device Daily – Other News to Note
Immunexpress Inc., of Seattle, reported a partnership with the DRIVe Solving Sepsis Initiative, a collaboration in which the Division of Research, Innovation...
Immunexpress Wins $745K HHS Contract for Rapid Sepsis Assay
Immunexpress said today that it has received a funding commitment of $744,739 from the US Department of Health and Human Services (HHS) for the development and commercialization of its SeptiCyte sample-to-result sepsis assay. The RT-qPCR assay, which received US Food and Drug Administration 510(k) clearance in early 2017, is...
Immunexpress Secures BARDA Contract for the Continued Development of SeptiCyte™ for the Rapid and Accurate Diagnosis of Sepsis
Immunexpress, Inc. today announced its partnership with the DRIVe Solving Sepsis Initiative, a collaboration in which DRIVe will contribute $744,739 of a $3.2M project for the development and commercialization of Immunexpress' SeptiCyte™ technology on the Biocartis Idylla™ platform. This development will result in a tool capable of a 90-minute, sample-to-result diagnosis in patients suspected...
Future In A Flash – Rollie Carlson CEO of Immunexpress
As the JP Morgan Healthcare Conference convenes in San Francisco, we’re offering a glimpse into the future of the industry, from the C-suites of the most promising pharma, biopharma, medtech, tech and telehealth companies in the nation. Today we explore the latest trends in rapid diagnostics with Immunexpress CEO, Rollie...
Sepset’s Sepsis Signature
BioCentury Senior Writer Michael Leviten discusses gene expression tests that could speed up diagnosis of sepsis.
Guard Against Sepsis In Your Chronic Heart Failure Patients
Sepsis is particularly deadly for CHF patients, and predictors of mortality include older age and chronic obstructive pulmonary disease. By Christopher Cheney.
Most People Don’t Know What Sepsis Is
September is Sepsis Awareness Month and part of the problem in fighting sepsis is that most people don’t know what it is, reports Westwood One. However, now there may be a faster way to detect it. Sepsis occurs when the body’s efforts to fight an infection trigger inflammation throughout the...
European and U.S. Patent Allowances Strengthen Immunexpress’ Leading Position in Host-Response Sepsis Diagnostics
Patent Allowances Relate to SeptiCyte™ Technology Using Biomarkers These allowances further reinforce the claims of the core family of patents that support the Company’s gene expression technology in the detection of host response to sepsis SEATTLE, Sept. 24, 2018 – Immunexpress, Inc., today announced the receipt of ‘Notices of Allowance’...
Avoidable Sepsis Infections Send Thousands Of Seniors To Gruesome Deaths
No one tracks sepsis cases closely enough to know how often these severe infections turn fatal. But the toll — both human and financial — is enormous, finds an investigation by KHN and the Chicago Tribune. By Fred Schulte and Elizabeth Lucas and Joe Mahr, Chicago Tribune.